IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,700.00
-40.00 (-0.52%)
Aug 8, 2025, 3:30 PM KST
-0.52%
Market Cap108.50B
Revenue (ttm)3.51B
Net Income (ttm)-8.39B
Shares Out14.02M
EPS (ttm)-598.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,402
Average Volume40,187
Open7,790.00
Previous Close7,740.00
Day's Range7,660.00 - 7,900.00
52-Week Range7,180.00 - 23,500.00
Betan/a
RSI39.22
Earnings Daten/a

About MorphoSys AG

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.

Financial Statements

News

There is no news available yet.